BridgeMD
New treatment option for Heart Failure With Reduced Ejection Fraction
Official title Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF
ClinicalTrials.gov ID: NCT06078436
What this study is testing
- What it's testing
- This study aims to compare the impact of hemodynamic monitoring using pulmonary artery catheter (PAC) on survival and inotropic agent reduction in patients with cardiogenic shock caused by heart failure with reduced ejection fraction (HFrEF). The investigators also intend to compare the difference in long-term survival rates among patients who have recovered from cardiogenic shock due to HFrEF, based on the timing of initiation of beta-blocker treatment.
- This is a blinded study.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 19 and older
You may be able to join if
- Adults age 19 and above ( no age limit for elderly )
- Patients with cardiogenic shock requiring intensive care monitoring in ICU
- Patients eligible for oral medication administration
- Patients who have provided research participation consent through a written informed consent form
You likely can't join if
- Unwilling or unable to obtain informed consent by the participant or substitute decision maker
- Patients with mechanical circulatory support at the time of screening
- Patients with acute coronary syndrome
- Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery
- Known hypersensitivity to beta-blockers
- Patients with a history of bronchospasm or asthma
See the full eligibility criteria
- Adults age 19 and above ( no age limit for elderly )
- Patients with cardiogenic shock requiring intensive care monitoring in ICU
- Patients eligible for oral medication administration
- Patients who have provided research participation consent through a written informed consent form
- Unwilling or unable to obtain informed consent by the participant or substitute decision maker
- Patients with mechanical circulatory support at the time of screening
- Patients with acute coronary syndrome
- Patients with severe valvular heart disease requiring emergent percutaneous procedures or surgery
- Known hypersensitivity to beta-blockers
- Patients with a history of bronchospasm or asthma
- Patients with bradycardia or second or third-degree atrioventricular block
- Patients with sick sinus syndrome, including sinoatrial block
- Patients with untreated pheochromocytoma
- Patients currently undergoing de-sensitization therapy
- Patients who are currently pregnant, postpartum period within 30 days or breast-feeding
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, South Korea
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 19 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.